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Antimitotic agents, including Taxol, disrupt microtu-
bule dynamics and cause a protracted mitotic arrest
and subsequent cell death. Despite the broad utility
of thesedrugs inbreast cancerandother tumor types,
clinical response remainsvariable.Tumor-associated
macrophages (TAMs) suppress the duration of Taxol-
induced mitotic arrest in breast cancer cells and
promote earlier mitotic slippage. This correlates
with a decrease in the phosphorylated form of his-
tone H2AX (gH2AX), decreased p53 activation, and
reduced cancer cell death in interphase. TAMs pro-
mote cancer cell viability following mitotic slippage
in a manner sensitive to MAPK/ERK kinase (MEK) in-
hibition. Acute depletion of major histocompatibility
complex class II low (MHCIIlo) TAMs increased
Taxol-induced DNA damage and apoptosis in cancer
cells, leading to greater efficacy in intervention trials.
MEK inhibition blocked the protective capacity of
TAMs and phenocopied the effects of TAM depletion
on Taxol treatment. TAMs suppress the cytotoxic
effects of Taxol, in part through cell non-autonomous
modulation of mitotic arrest in cancer cells, and
targeting TAM-cancer cell interactions potentiates
Taxol efficacy.INTRODUCTION
The microenvironment plays a critical role in regulating tumor
development and disease progression (Quail and Joyce, 2013).
In the context of chemotherapy treatment, tumor-associated
macrophages (TAMs) have emerged as potent regulators of ther-
apeutic response (De Palma and Lewis, 2013; Ruffell and Cous-
sens, 2015). These effector cells can modulate cancer cell sur-
vival pathways through the provision of cytokines (Mitchem
et al., 2013) and pro-tumorigenic proteases (Shree et al., 2011).This is an open access article under the CC BY-NAdditionally, TAMs can suppress immune-based mechanisms
of cytotoxic chemotherapy (DeNardo et al., 2011; Ruffell et al.,
2014). Limited research, however, has been conducted into
whether microenvironment cells, including TAMs, directly affect
themolecular mechanisms by which cytotoxic chemotherapy in-
duces cancer cell damage.
Some intriguing insights into this question have emerged from
intravital imaging experiments, showing that antimitotic agents
in particular have impaired efficacy against cancer cells in vivo
versus what is observed in monoculture in vitro (Orth et al.,
2011). Whereas cancer cells propagated in culture arrest for pro-
longed periods of time following exposure to high doses of antimi-
totic drugs, often dying duringmitosis, when the same cancer cell
lines are grown in vivo, they arrest for shorter periods and exit
mitosis without dividing in a process termed mitotic slippage
(Orth et al., 2011). These results suggest that a microenviron-
mental component may influence the fate of cancer cells in vivo
compared with in vitro. Additionally, the observations that extra-
cellular factors canpromoteefficientcentrosomeseparation (Mar-
din et al., 2013) or drive clustering of supernumerary centrosomes
(Kwon et al., 2008) suggest a potential role for the microenviron-
ment in regulating mitosis, which has generally been considered
acell-autonomousprocess.Thus,wesought toevaluate theeffect
of TAMsonmitotic arrest of cancer cells and their subsequent fate
in the context of chemotherapy treatment with Taxol.RESULTS
TAM Depletion Increases Taxol-Induced DNA Damage
Signaling and Cell Death
In order to determine the role of TAMs in the acute response
to treatment with the antimitotic agent Taxol, we designed a
1-week trial in which TAMs were depleted with BLZ945, a
small-molecule inhibitor of the colony stimulating factor-1 recep-
tor (CSF-1R) (Pyonteck et al., 2013), immediately prior to chemo-
therapeutic treatment (Figure 1A). FVB/n female mice were
orthotopically implanted via mammary fat pad injection with
the MMTV-PyMT breast cancer cell line, TS1 (Shree et al.,
2011). Following tumor establishment, mice were treated withCell Reports 19, 101–113, April 4, 2017 ª 2017 The Authors. 101
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Depletion of TAMs Increases gH2AX Levels in Response to Taxol Treatment
(A) Preclinical trial design for combined CSF-1R inhibition and Taxol treatment in an orthotopic mouse model of breast cancer following mammary fad pad (MFP)
injection of the TS1 tumor cell line and subsequent tumor establishment.
(B) Plot of tumor volume as a function of time. Treatment groups are vehicle (VEH) 20% Captisol, BLZ945 (BLZ), and Taxol (TAX). Vertical arrow indicates t = 0
when Taxol was administered. The vehicle was administered daily to all animals in the Taxol alone group.
(C) Quantification by image analysis of intratumoral CD68+ cells at 24, 48, and 72 hr after Taxol treatment.
(legend continued on next page)
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BLZ945 for 72 hr prior to a single dose of Taxol and continued on
BLZ945 in a time course for a further 24–96 hr. It is known that
prolonged CSF-1R inhibition (using a chemically distinct small-
molecule inhibitor, PLX3397) in combination with Taxol in pre-
clinical breast cancer models leads to improved efficacy over
time through increased chemotherapy-induced activation of
a CD8+ T cell-mediated immune response (DeNardo et al.,
2011). For this reason, we restricted our initial analyses to the
time points immediately following Taxol treatment, when no sig-
nificant tumor volume differences were yet observed between
Taxol versus Taxol + BLZ945 (Figure 1B). Our preclinical trial
design for these initial experiments, therefore, focuses on the
acute phase of drug response, enabling precise assessment of
the effects of TAM depletion on the cancer cell response to Taxol
in vivo through a series of time points.
Pretreatment with BLZ945 led to a 47% reduction in TAMs
at the time of Taxol administration (day 0) as measured by
immunofluorescence staining and quantification of intratumoral
CD68+ cells in tissue sections (Figure 1C). By the trial endpoint,
BLZ945-treated tumors had 75% fewer CD68+ cells relative to
those tumors treated with Taxol alone (Figure 1C). To determine
the effects of TAM depletion on the cancer cell response to Taxol
treatment, we stained tissue sections for various markers of
DNA damage, cell death, and proliferation. A marker of DNA
double-strand breaks, the phosphorylated form of histone
H2AX (gH2AX), can be used as a means to monitor the effective-
ness of cancer therapeutics (Bonner et al., 2008). We found that
BLZ945 treatment led to substantially increased levels of
gH2AX+ cells at both 24 and 72 hr post-Taxol compared with
Taxol alone (Figure 1D). This correlatedwith significantly elevated
levels of cleaved caspase-3+ (CC3+) apoptotic cells at 48 hr after
Taxol treatment (Figure 1E). Additionally, BLZ945 significantly
reduced proliferation at 24 hr post-Taxol treatment as measured
by Ki67 staining (Figure 1F). Collectively, these data indicate that
in the context of Taxol treatment, TAM depletion is associated
with enhanced DNA damage signaling, increased apoptosis,
and suppression of proliferation in cancer cells, suggesting a
role for TAMs in modulating the cytotoxic activity of this antimi-
totic agent.
We next sought to determine whether TAM depletion altered
the bioavailability or potency of Taxol within the tumor. Given
that the mechanism of action of Taxol involves microtubule sta-
bilization (Schiff and Horwitz, 1980), and stabilized microtubules
become acetylated (Schulze et al., 1987), we measured intratu-
moral a-tubulin acetylation as a surrogate marker of intratumoral
Taxol bioavailability. We observed increased levels of a-tubulin
acetylation in tumors following Taxol treatment, with no signifi-
cant difference compared with tumors additionally treated with
BLZ945 (Figure S1A). Moreover, the percentage of phospho-his-
tone H3+ mitotic cells increased similarly in both control and
BLZ945-treated mice following Taxol treatment (Figure S1B),
showing that the accumulation of mitotic cells is similar in both
conditions. These data indicate that macrophages do not inter-(D–F) Quantitation of the percentage of (D) gH2AX+, (E) cleaved caspase-3+ (CC3
sections (right). Scale bars, 50 mm. n = 5 mice in all treatment groups at all time
(C–F) Data are from whole tumors isolated at the indicated time points according
Student’s t test was used to assess significance between treatment groups: *p <fere with the bioavailability of Taxol nor do they prevent cells
from entering mitotic arrest. Rather, TAMs likely directly affect
the cytotoxicity of Taxol upon cancer cells.
Because of the complexity of TAM and myeloid cell popula-
tions in breast tumors (DeNardo et al., 2011; Franklin et al.,
2014), we wanted to determine which specific macrophage
subsets are altered in response to acute CSF-1R inhibition. We
were particularly interested in the relative depletion of major his-
tocompatibility complex class II high (MHCIIhi) and low (MHCIIlo)
macrophage populations following BLZ945 treatment because
of their reported phenotypic differences (Franklin et al., 2014)
and differential dependency on CSF-1R signaling (Van Over-
meire et al., 2016). We observed that following 72 hr of BLZ945
pretreatment there were significant reductions in both MHCIIlo
and MHCIIhi populations of CD11b+ F4/80+ macrophages rela-
tive to total CD45+ leukocytes (day 0 of the trial; Figures S1C
and S1D). However, only the relative proportion of MHCIIlo mac-
rophages remained significantly reduced in the context of Taxol
treatment (Figures S1C and S1D), consistent with the critically
important role of CSF-1R signaling in this specific TAM popula-
tion (Van Overmeire et al., 2016). Additionally, there were signif-
icant increases in CD4+ and CD8+ T cells in BLZ945-pretreated
tumors at the time of Taxol administration (Figures S1E and
S1F). This elevation in T cell numbers following CSF-1R inhibition
and macrophage depletion is consistent with previous reports
(DeNardo et al., 2011; Strachan et al., 2013). Collectively, these
data indicate that the depletion of MHCIIlo TAMswithin the tumor
microenvironment correlates with increased cancer cell DNA
damage and apoptosis, and decreased proliferation in cancer
cells. Moreover, this suppression of cytotoxic activity is achieved
without altering the ability of Taxol to stabilize microtubules and
induce mitotic arrest.
Macrophage-Secreted Factors Suppress DNA Damage
Signaling and Cell Death following Taxol-Induced
Mitotic Arrest
To determine whether TAMs suppress Taxol-induced cytotoxic
stress though direct interaction with cancer cells or via another
component of the tumor microenvironment, we sought to inves-
tigate whether we could model our in vivo findings in a recon-
structed in vitro system. Cancer cells are known to respond to
antimitotic agents with high levels of intra- and inter-cell line
variation (Gascoigne and Taylor, 2008). To this end, we first
characterized the TS1 murine breast cancer cell response to
Taxol. When we treated TS1 cells with Taxol in monoculture,
we observed a loss of 2C DNA content cells by 24 hr, indicating
that in response to Taxol treatment, cancer cells were unable to
successfully divide and return to a diploid G1 cell state (Fig-
ure S2A). This correlated with the emergence at 24 hr of a higher
DNA content tetraploid (4C) peak, and at 48 hr of a higher DNA
content 8C peak, indicative of tetraploid cells that had re-entered
the cell cycle following a failed cell division. In addition, a sub-2C
peak indicative of fragmented apoptotic nuclei emerged at 48 hr+), and (F) Ki67+ cells within the tumor (left) and representative images of tumor
points. All data are presented as mean ± SEM.
to the trial design in (A).
0.05; **p < 0.01; ***p < 0.001. See also Figure S1.
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and increased at 72 hr (Figure S2A). Examination of the nuclear
morphology of cells treated for 24 hr with Taxol revealed
that the majority of the cells display a multinucleated phenotype
(Figure S2B). This phenotype is indicative of mitotic slippage
following Taxol-induced mitotic arrest (Panvichian et al., 1998).
Thus, we find that the majority of TS1 cancer cells undergo
mitotic slippage and become tetraploid within 48 hr following
Taxol treatment, and that cell death is typically observed at sub-
sequent time points. This is consistent with intravital microscopy
studies that have demonstrated this mechanism of action for
maximum tolerated dose Taxol treatment in vivo (Chittajallu
et al., 2015; Orth et al., 2011).
We next cultured TS1 tumor cells with bone marrow-derived
macrophages (BMDMs) and assessed whether there were any
alterations to the DNA content changes in response to Taxol.
Notably, we found that co-culture with macrophages substan-
tially reduced the accumulation of sub-2C apoptotic tumor cells
at 48 and 72 hr (Figure 2A). This correlated with increased pop-
ulations of 4C and 8C DNA content cells at 72 hr, indicating
that macrophage co-culture promoted the persistence of can-
cer cells following Taxol-induced mitotic slippage (Figure 2A).
Similar to our observations in vivo, in cell culture there was
no impact of macrophages on the ability of Taxol to increase
the percentage of phospho-histone H3+ mitotic cancer cells
as measured by flow cytometry (Figure 2B). By contrast,
when gH2AX immunoreactivity was measured in cancer cells
following Taxol treatment, we found that co-culture with BMDMs
significantly reduced the percentage of gH2AX+ cancer cells
throughout the time course analyzed (Figure 2C). Furthermore,
we also found that macrophage co-culture transiently reduced
the number of cancer cells with phosphorylation of p53 (Fig-
ure 2D), an important suppressor of cell growth following failed
cytokinesis (Andreassen et al., 2001). These data demonstrate
that BMDMs are able to directly suppress the ability of Taxol to
induce markers of genotoxic stress, such as gH2AX, in cancer
cells.
Given the differential depletion of MHCIIlo versus MHCIIhi TAM
populations that we observed in response to prolonged CSF-1R
inhibition in vivo, we next assessed whether MHCII+ BMDMs
were capable of suppressing genotoxic stress and cell death in
response to Taxol. MHCII expression was induced on BMDMs
by treatment with CSF-2 and interferon g (IFNg) for 48 hr prior
to co-culturewith cancer cells (Figure S2C). Interestingly,MHCII+
BMDMs were unable to suppress cell death or the induction of
gH2AX in cancer cells (Figure 2E), indicating that the in vivo ef-Figure 2. Macrophages Suppress Genotoxic Stress and Cancer Cell D
TS1 tumor cells (TCs) were cultured with Taxol and assayed by flow cytometry a
(A–D) Flow cytometric analysis of DNA content (n = 4 independent experiments) (
immunoreactivity (n = 3 independent experiments) (C), and phospho-p53 immun
Taxol treatment (50 nM), and the effects of co-culture with bone marrow-derived
(E) Comparison of the effects of co-culture with MHCII+ BMDMs on Taxol-induc
noreactivity (n = 4 independent experiments).
(F) Comparison of the effects of direct cell co-culture versus BMDM-conditione
accumulation of tumor cells with sub-2C DNA content and gH2AX immunoreact
(G) Quantification of caspase activation in response to Taxol treatment and the ef
blots are shown on the left, and quantification of each caspase is shown on the
All data are presented as mean ± SEM. Student’s t test was used to assess signifi
Figures S2 and S3.fects of BLZ945 treatment on Taxol response are likely due to
the specific depletion of the MHCIIlo population of TAMs, rather
than simply reducing the number of TAMs overall.
Additionally, we assessed the ability of other stromal cell lines
representative of the breast tumormicroenvironment for the abil-
ity to suppress the cytotoxic effects of Taxol (Figure S2D). We
tested two fibroblast cell lines isolated from different stages of
MMTV-PyMT tumor development (AdAF, CAF1) (Calvo et al.,
2013) and twomurine endothelial cell lines (EOMA, C166) (Obeso
et al., 1990; Wang et al., 1996). No significant effects were
observed upon co-culture of TS1 cancer cellswith these different
stromal cell types (Figure S2D), further indicating that the robust
suppression of gH2AX and cancer cell death is a functional role
unique to macrophages and specifically the MHCIIlo population.
We were also interested in determining whether macrophages
were similarly capable of reducing gH2AX levels in response
to mechanistically distinct chemotherapeutic agents; thus, we
treated co-cultures with carboplatin, doxorubicin, etoposide,
or gemcitabine. For all chemotherapies tested we observed a
reduction in gH2AX levels in cancer cells in the presence of mac-
rophages (Figure S2E), although not all to the same extent as for
Taxol treatment (Figure 2C). These observations correlated with
increased cancer cell viability in the case of doxorubicin, etopo-
side, and gemcitabine, but not carboplatin (Figure S2F). Thus,
although TAMs can generally reduce DNA damage signaling in
cancer cells, the effect on cancer cell fate appears to be specific
to the chemotherapeutic agent assessed.
In order to better understand the means by which macro-
phages suppress cancer cell genotoxic stress in response to
chemotherapy, we asked whether the effect could be replicated
using macrophage-conditioned media (CM). CM was generated
from BMDMs (BMDM-CM) and added to TS1 cells at plating and
at the start of the 72 hr experiment (Figure S2G). This partially
replicated the reductions in cancer cell death and gH2AX levels
observed with direct cell co-culture. However, when the experi-
mental protocol was modified from a single addition of CM at the
start of treatment (Figure S2G) to supplementation with fresh CM
daily [BMDM-CM(+)], the effects of direct cell co-culture could
be fully recapitulated (Figure 2F). These findings indicate that
the protective factor(s) is secreted by macrophages, because it
is not dependent on direct cell-cell contact between macro-
phages and cancer cells. Furthermore, cancer cells are appar-
ently dependent upon regular replenishment of this factor(s)
from macrophages in order to receive the maximal protective
benefit. Previously we have shown that macrophage-secretedeath
t the indicated time points.
A), phospho-H3 immunoreactivity (n = 3 independent experiments) (B), gH2AX
oreactivity (n = 3 independent experiments) of the TS1 TC line in response to
macrophages (BMDMs) (D).
ed accumulation of tumor cells with sub-2C DNA content and gH2AX immu-
d media (CM) supplemented daily [denoted BMDM-CM(+)] on Taxol-induced
ivity (n = 4 independent experiments).
fects of BMDM-CM as measured by western blotting. Representative western
right (n = 3 independent experiments).
cance between treatment groups: *p < 0.05; **p < 0.01; ***p < 0.001. See also
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Figure 3. Macrophage-Secreted Factors Reduce the Duration of Taxol-Induced Mitotic Arrest
TS1 tumor cells were imaged live with or without co-culture with GFP-expressing BMDMs.
(A) Representative images of assays in which cells were imaged by differential interference contrast (DIC) microscopy. BMDMs were identified by GFP fluo-
rescence imaging and excluded from mitotic analyses.
(B) Montage of individual TS1 cells entering mitosis and exiting by mitotic slippage. Numbers indicate time relative to mitotic entry in minutes. Scale bars, 10 mm.
(C) A single representative experiment is plotted measuring the duration of mitotic arrest in TS1 cells treated with Taxol (50 nM) in the presence or absence of
BMDMs. In each experiment, at least 30 cells were scored per condition, and this was repeated in three independent experiments.
(legend continued on next page)
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cathepsin proteases have an anti-apoptotic effect in the context
of chemotherapeutic treatment (Shree et al., 2011). We therefore
evaluated whether cathepsin inhibition specifically altered the
ability of macrophages to reduce gH2AX levels and nuclear frag-
mentation, and we found no difference (Figures S3A and S3B).
This indicates that there aremultiple mechanisms bywhichmac-
rophages can interfere with chemotherapy efficacy.
We next asked which component of the macrophage-CMwas
responsible for the protective activity, which is defined herein by
reduced gH2AX levels and accumulation of sub-2C cancer cells
following Taxol treatment. Fractionation of the macrophage-CM
using molecular weight cutoff spin columns determined that
the protective activity was specific to the >3 kDa fraction (Fig-
ure S3C). Therefore, we reasoned that the macrophage-derived
factor(s) is unlikely to be a small-molecule metabolite and is
probably proteinaceous in nature. We also treated cancer cells
withmacrophage-CM and saw no alteration in the ability of Taxol
to induce tubulin acetylation (Figure S3D), a marker of microtu-
bule stabilization (Schulze et al., 1987). Thus, as with our in vivo
findings, macrophages do not appear to interfere with the ability
of Taxol to stabilize cancer cell microtubules, but rather alter the
downstream effectors of this treatment.
We next examined whether BMDM-CM alters the activation
of apoptotic pathways in response to Taxol treatment by three
independent measures: caspase cleavage, ‘‘mitochondrial prim-
ing,’’ and MCL1 degradation. We determined that the presence
of BMDM-CM reduced the cleavage of caspase-8, -9, and -3,
suggesting impaired activation of both initiator and effector cas-
pases (Figure 2G). To assess mitochondrial priming within the
cancer cells (Vo et al., 2012), we treated cancer cells at various
time points following Taxol addition with the BH3 mimetic
ABT-263 to induce mitochondrial depolarization. We observed
no effect of macrophage-CM on cancer cell sensitivity to ABT-
263 either before or after Taxol treatment (Figure S3E). Addition-
ally, there were no significant effects of macrophage-CM on
Taxol-induced MCL1 degradation, or levels of other BCL2 family
members (Figure S3F). Therefore, macrophage-CM impairs the
ability of Taxol to activate apoptotic caspases, but in a manner
that does not make the cells generally resistant to mitochondrial
depolarization and apoptosis. Our data thus suggest that the
macrophage-supplied activity specifically impairs the ability of
mitotic arrest to induce cytotoxic stress and the subsequent
initiation of apoptosis in cancer cells.
Macrophages Reduce the Duration of Cancer Cell
Mitotic Arrest
To understand how macrophage-secreted factors alter the con-
sequences of Taxol-inducedmicrotubule stabilization and inhibit
cancer cell death, we focused on mitotic arrest, the critical inter-
mediate step. To this end, we cultured cancer cells with macro-(D) As in (C), except that tumor cells were additionally treated with complete or f
(E) Clonogenic assay measuring the effects of BMDM-CM on inhibition of tumor c
quantification of crystal violet staining is shown on the right (n = 3 independent e
(F) DNA content analysis of tumor cell colonies shown in (E) at day 8 (n = 4 inde
quantification of treatment groups on the right.
Data for mitotic arrest duration are presented as mean ± interquartile range. All o
significance between treatment groups. *p < 0.05; **p < 0.01; ***p < 0.001. ns, nphages andmeasured the duration of cancer cell mitotic arrest in
response to Taxol using live imagingmicroscopy (Figure 3A). The
duration of mitotic arrest was measured as the time between cell
rounding and mitotic slippage (Figure 3B). We observed that the
vast majority of mitotic arrests ended in mitotic slippage rather
than death in mitosis (data not shown). When cancer cells
were cultured with macrophages, this resulted in a significant
reduction in the duration of mitotic arrest (Figure 3C). To control
for any effects of cell density, we plated cancer cells at an
increased concentration with no significant impact on the dura-
tion of Taxol-induced mitotic arrest (Figure S4A). Additionally,
we replicated these findings using the mechanistically distinct
inhibitor of the mitotic kinesin Eg5, S-trityl-L-cysteine (STLC)
(Figure S4B), demonstrating that macrophage co-culture re-
duces the duration of mitotic arrest in response to multiple spin-
dle poisons. Given the ability of macrophage-CM to replicate the
effects of direct co-culture on gH2AX signaling and cancer cell
death, we sought to determine whether macrophage-secreted
factors were also responsible for modulating mitotic arrest. We
observed that macrophage-CM was indeed sufficient to reduce
the duration of Taxol-induced mitotic arrest in cancer cells (Fig-
ure 3D). Moreover, fractionation of the CM indicated that the
>3 kDa CM fraction was responsible for shortening the duration
of mitotic arrest in cancer cells (Figure 3D), consistent with this
fraction also reducing levels of gH2AX and apoptosis in Taxol-
treated TS1 cells (Figure S3C).
The duration ofmitotic arrest has been proposed to dictate cell
fate in response to microtubule-stabilizing agents (Bekier et al.,
2009) and to determine the extent of multinucleation and DNA
damage following mitotic slippage (Zhu et al., 2014). In order to
uncouple the effects of prolonged mitotic arrest and failed cyto-
kinesis in our experimental system, we used the aurora B kinase
inhibitor ZM447439 to abrogate the Taxol-induced mitotic arrest
and promote rapid mitotic slippage. Treatment with ZM447439
significantly reduced the induction of gH2AX and p53 activation
at 24 hr (Figures S4C and S4D). These data confirm that pro-
tracted mitotic arrest is required for Taxol-induced genotoxic
stress at the 50 nM concentration used here (Bekier et al.,
2009; Zhu et al., 2014). Recent work has suggested that mitotic
arrest is not required for response to Taxol, arguing that clinically
relevant concentrations of Taxol are actually in the low nanomo-
lar range (Zasadil et al., 2014). We therefore assessed the ability
of various concentrations of Taxol to induce accumulation of
TS1 cells arrested in mitosis following 8 hr of treatment (Fig-
ure S4E). We observed significant increases in phospho-H3+
cells at 6.25 and 12.5 nM with more pronounced increases
occurring at concentrations of 25 nM and above (Figure S4E).
Indeed, when we examined the DNA content profiles of the cells
after 24 hr of treatment, we observed that although at 6.25 nM
the profile was unperturbed, at 25 nM the DNA content profileractionated macrophage-CM (<3 kDa or >3 kDa fractions).
ell colony formation by Taxol. Representative images are shown on the left, and
xperiments). Scale bar, 5 mm.
pendent experiments). Representative histograms are shown on the left, with
ther data are presented as mean ± SEM. Student’s t test was used to assess
on-significant. See also Figure S4.
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Figure 4. Tumor Cell MAPK Signaling Is Critical for Viability following Taxol Treatment
(A) Analysis of ERK1/2 signaling in tumor cells in response to treatment with Taxol (50 nM) in the presence or absence of BMDM-CM supplemented daily [denoted
BMDM-CM(+)]. Representative western blots are shown. Area under the curve (AUC) quantification of band intensities is displayed in the graph below as a ratio of
phosphorylated/total ERK1/2 (n = 3 independent experiments).
(B) Flow cytometric analysis of sub-2CDNA content tumor cells in response to Taxol (50 nM) and theMEK inhibitor PD0325901 (500 nM). Tumor cells were treated
alone or in co-culture with BMDMs (n = 3 independent experiments).
(C) Analysis of ERK1/2 signaling and caspase-3 activation in tumor cells following 48 hr of treatment with Taxol (50 nM) in the presence or absence of
BMDM-CM(+) and the MEK inhibitor PD0325901 (500 nM). Representative western blots are shown. AUC quantification of band intensities is displayed to the
right as a ratio of CC3+/GAPDH (n = 3 independent experiments).
(legend continued on next page)
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was indicative of failed cell division in most cells (Figure S4F).
At 12.5 nM concentrations of Taxol we saw an intermediate
phenotype, suggesting mixed mitotic slippage and successful
cell division (Figure S4F). We next sought to determine whether
macrophages were still protective against the cytotoxic effects
of Taxol at these lower concentrations. At both lower concentra-
tions, we observed significant reductions in cancer cell death
with BMDM co-culture (Figure S4G). However, the induction of
cell death at the 6.25 nM Taxol concentration, where we did
not observe mitotic slippage and increased cancer cell ploidy,
was minimal.
Given the ability of macrophages to support the survival of
cancer cells following Taxol-induced mitotic slippage, we
were interested in assessing the long-term fate of these newly
tetraploid cells. There are several alternative outcomes for
cells following mitotic slippage besides cell death or continued
proliferation (Vitale et al., 2011), and although the cells may
remain viable, this can occur with a loss of self-renewal capac-
ity if they arrest and become quiescent or senescent. Thus,
we sought to examine the effects of macrophage-CM on Taxol
treatment in a clonogenic cell survival assay. Cancer cells
treated with Taxol in the presence of macrophage-CM formed
significantly more colonies than those treated with Taxol alone
(Figure 3E). Furthermore, when we assessed the DNA content
from the cells in these colonies, we found a greater proportion
of tetraploid (4C) cells in the macrophage-CM-treated sam-
ples (Figure 3F). When we used lower concentrations of Taxol,
we also observed increased clonogenic capacity in cells
treated with macrophage-CM (Figure S4H). These data indi-
cate that macrophage-CM promotes the proliferative viability
of cancer cells following Taxol-induced mitotic slippage and
tetraploidization.
Cancer Cell Mitogen-Activated Protein Kinase Signaling
Is Critical for Viability following Taxol Treatment
High levels of mitogen-activated protein kinase (MAPK) have
been reported to drive both intrinsic and acquired resistance
to taxanes (Cheung et al., 2004; McDaid and Horwitz, 2001; Me-
nendez et al., 2005). Furthermore, inhibitors targeting the MAPK
pathway have been shown to potentiate the effects of Taxol
in vivo (Holt et al., 2012; McDaid et al., 2005). When we assessed
MAPK signaling following Taxol treatment, we observed that
macrophage-CM led to a maintenance of extracellular signal-
regulated kinase (ERK) 1/2 phosphorylation, whereas the levels
in cancer cells treated alone were significantly reduced at 24
and 48 hr (Figure 4A). Treatment of co-cultured macrophages
and cancer cells with an MAPK/ERK kinase (MEK) inhibitor
(PD0325901) blocked the protective effect of macrophages (Fig-
ure 4B). This effect was specific to MAPK pathway inhibition(D) Clonogenic assay measuring the effects of the MEK1/2 inhibitor PD0325901 an
Representative images are shown on the left, and quantification of crystal violet s
(E) Tumor volume plots for the assessment of response to a single dose of Taxol (in
Figure S5E for schematic of trial design. n = 10 mice in all treatment groups.
(F) Tumor volume plots for the assessment of response to weekly Taxol treatme
BLZ945 treatment. See Figure S6B for schematic of trial design. n = 10 mice in a
All data are presented as mean ± SEM. Student’s t test was used to assess signifi
Figures S5 and S6.because protein kinase b (AKT) inhibition was insufficient to
block the protective effect of macrophages in the context of
Taxol treatment (Figures S5A and S5B). Given the reported
importance of the epidermal growth factor (EGF)/CSF-1 para-
crine loop in TAM-cancer cell communication within the tumor
microenvironment (Wyckoff et al., 2004), and the position of
EGF receptor (EGFR) upstream of the MAPK pathway (Roberts
and Der, 2007), we asked whether this signaling axis was critical
to the protective effect of macrophages observed here. Co-cul-
tures of BMDMs and cancer cells were treated with Taxol, with or
without the EGFR inhibitor gefitinib (Figure S5C). However, this
did not significantly affect Taxol-induced cell death. In order
to determine whether cell-autonomous MAPK inhibition in the
cancer cells was indeed responsible for reversal of the Taxol-
induced cell death phenotype, and to exclude any confounding
effect of MAPK inhibition in macrophages, we repeated the
assay using macrophage-CM and similarly saw restoration of
cell death with MEK inhibition (Figure S5D). MEK inhibition also
blocked the ability of macrophage-CM to reduce the duration
of Taxol-induced mitotic arrest (Figure S5E). Although MEK inhi-
bition has been reported to enhance death in mitosis in response
to prolonged mitotic arrest by microtubule inhibitors (Kawabata
et al., 2012), we observed no effect of MEK inhibition alone
on Taxol-induced mitotic arrest (Figure S5E), possibly because
of the bias of the TS1 cell line toward mitotic slippage. MEK
inhibition also restored caspase-3 cleavage in macrophage-
CM treated samples (Figure 4C). Thus, targeting the MAPK
pathway in combination with Taxol potentiates cancer cell death
and blocks the ability of macrophages to modulate mitotic arrest
and mediate therapeutic resistance.
Given the ability of MEK inhibition to restore cell death in
the presence of macrophage-CM, we sought to determine the
effect of inhibition on clonogenic survival of cancer cells in the
context of Taxol treatment. Addition of the MEK inhibitor led
to a 53% reduction in outgrowth of cells treated with Taxol
and macrophage-CM, to a level comparable with Taxol treat-
ment alone (Figure 4D). Furthermore, when we analyzed the
DNA content of the colonies, we observed that the MEK inhib-
itor reduced the ploidy of the Taxol treatment groups (Fig-
ure S5F). Interestingly, we also observed that macrophage-
CM significantly blocks the reduction in clonogenic capacity
of cancer cells treated with the MEK inhibitor alone. We addi-
tionally found that macrophage-CM reversed the reduction in
NF-kB p65 activation observed with MEK inhibitor treatment
(Figure S5G). Collectively, our data indicate that macrophage-
secreted factors can suppress Taxol-induced cytotoxic stress
and promote proliferative viability following mitotic slippage in
a manner sensitive to MAPK inhibition in the cancer cells
(Figure S6A).d BMDM-CM onmodulating inhibition of tumor cell colony formation by Taxol.
taining is shown on the right (n = 4 independent experiments). Scale bar, 5 mm.
dicated by vertical dotted line) and acute BLZ945 or PD0325901 treatment. See
nt (indicated by vertical dotted lines) with concurrent PD0325901 or sustained
ll treatment groups.
cance between treatment groups: *p < 0.05; **p < 0.01; ***p < 0.001. See also
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Acute CSF-1R and MEK Inhibition Potentiate the
Response to Taxol
In order to determine whether targeting the interactions between
TAMs and breast cancer cells could modulate the therapeutic
response to Taxol in vivo, we designed a trial that combined a
single dose of Taxol with acute BLZ945 and/or PD0325901 treat-
ment, followed by trial endpoint analyses 15 days after Taxol
administration (Figure S6B). As above, BLZ945 was adminis-
tered for 3 days to deplete TAMs prior to Taxol treatment, then
continued concurrently with Taxol treatment for an additional
3 days. PD0325901 treatment was initiated with Taxol treatment
and continued for 3 days (Figure S6B). In this manner, we aimed
to confine the inhibitor treatment to the time window when
cancer cells are directly responding to Taxol treatment and
then monitor subsequent tumor regrowth. Neither BLZ945 nor
PD0325901, nor the combination of these two inhibitors, had a
significant impact on tumor volumes at endpoint (Figure 4E).
In combination with Taxol treatment, however, all acute treat-
ment groups had significantly lower tumor volumes at endpoint
compared with Taxol alone (Figure 4E). Notably, no additive
effect was observed from the triple combination of BLZ945 +
PD0325901 + Taxol treatment versus the single drugs combined
with Taxol (Figure 4E).
When we analyzed tissues taken at 72 hr following Taxol
treatment, we found that as observed previously for BLZ945
treatment, combined treatment with PD0325901 increased intra-
tumoral gH2AX+ and CC3+ cells (Figures S6C and S6D). We next
sought to validate these findings in a trial aimed at tumor control
where Taxol was administered weekly. Whereas PD0325901
treatment still remained confined to 3 days concurrent with Taxol
administration, BLZ945 treatment was now continuous (Fig-
ure S6E). As in the earlier trials, we observed a significant reduc-
tion in endpoint tumor volume in animals treated with either
BLZ945 or PD0325901 in combination with Taxol compared
with those treated with Taxol alone (Figure 4F). Interestingly,
both inhibitors are essentially interchangeable with respect to
potentiation of Taxol, which is consistent with our workingmodel
of each inhibitor targeting the same protective interaction of
TAMs and cancer cells (Figure S6A).
DISCUSSION
Here, we report that depletion of MHCIIlo TAMs via CSF-1R
inhibition increases the levels of cancer cell DNA damage
signaling and cell death in response to Taxol treatment in a pre-
clinical model of breast cancer. Macrophage-secreted factors
are capable of suppressing induction of multiple markers of
genotoxic stress and reducing activation of both the intrinsic
and the extrinsic apoptotic pathways in response to Taxol-
induced mitotic arrest and slippage. This occurs in association
with a reduction in the duration of cancer cell mitotic arrest; this
is the first example of non-autonomous modulation of mitotic
arrest by stromal cells that we are aware of. Macrophages
also act on subsequent steps by promoting the clonogenic
viability of these newly tetraploid cancer cells in a manner sen-
sitive to MAPK inhibition. Identification of the secreted factor(s)
is an active area of research in the laboratory, and we expect
this to provide important further insights into the mechanisms110 Cell Reports 19, 101–113, April 4, 2017by which macrophages confer protection against different
chemotherapies.
Previously, the role of the tumor microenvironment in medi-
ating chemoresistancewas largely demonstrated to be the result
of impaired pharmacokinetics and increased survival signaling
(Klemmand Joyce, 2015). Our study and other recent work (Hou-
thuijzen et al., 2014), however, demonstrate the ability of the
environment to also modulate the mechanisms through which
chemotherapeutic agents induce cytotoxic stress in cancer
cells. Intravital microscopy has been particularly informative in
evaluating the response to chemotherapy in an intact tumor
microenvironment (Nakasone et al., 2012). In this manner, other
groups have observed that antimitotic agents lead to shorter
mitotic arrest and mitotic slippage in vivo (Chittajallu et al.,
2015; Orth et al., 2011). Our data are consistent with these
studies and now identify a specific role for TAMs in modulating
the mitotic arrest of cancer cells in an intact tumor microenviron-
ment. This paradigm of attenuated response to Taxol treatment
in vivo is supported by clinical studies, where serial fine-needle
aspirations of breast cancer patients undergoing treatment re-
vealed a greater number of apoptotic cells than cells arrested
inmitosis, and responder patients showed a sustained apoptotic
response even after levels of mitotic cells had returned to base-
line (Symmans et al., 2000). These findings are consistent with
mitotic slippage of the cancer cells in vivo, followed by subse-
quent apoptosis of the tetraploid cells in interphase (Figure S6A),
rather than the classical model of death in mitosis following a
prolonged arrest. The ability of the tumor microenvironment
to support the viability of cancer cells after failed cell division is
corroborated by reports that enhanced growth factor signaling
can overcome p53-induced G1 arrest (Ganem et al., 2014).
The ultimate fate of these cells, however, remains an open ques-
tion. Tetraploidization has been shown to promote chromo-
somal instability, tolerance to mitotic errors, and enhanced can-
cer genome evolution (Dewhurst et al., 2014; Kuznetsova et al.,
2015). Aneuploid cells, however, have also been shown to prolif-
erate at slower rates, and thus Taxol-induced tetraploidization
might reduce overall tumor growth (Williams et al., 2008).
We have also demonstrated herein that pro-tumorigenic inter-
actions between cancer cells and TAMs can be efficiently tar-
geted via either cellular component, because MEK and CSF-1R
inhibitors were interchangeable in potentiating the response to
Taxol treatment. Although themicroenvironment hasbeenshown
to mediate resistance to both conventional and targeted thera-
peutics (Klemm and Joyce, 2015; Straussman et al., 2012), mul-
tiple drug combinations will likely suppress microenvironmental
interference.Ultimately, it is becoming clear that the tumormicro-
environment can regulate numerous aspects of resistance to
therapeutic intervention and in this manner influence cancer
cell heterogeneity. Consequently, therapeutic strategies that
consider and account for the influence of the microenvironment,
including TAMs, will be critical to improve clinical outcomes.EXPERIMENTAL PROCEDURES
Culture of Established Cell Lines and Drug Treatments
All cell lines were maintained in high-glucose DME media supplemented with
10%fetal bovineserum,2mMglutamine, and100U/mLpenicillin/streptomycin.
The TS1 cell linewas derived in J.A.J.’s laboratory as previously reported (Shree
et al., 2011). CAF1 and AdAF lines were provided by Dr. Erik Sahai (Calvo et al.,
2013). EOMA and C166 cell lines were purchased from the ATCC (Obeso et al.,
1990; Wang et al., 1996). Where indicated, 50 nM Taxol (Sigma), 50 mM carbo-
platin (Selleckchem), 300 nM doxorubicin (Selleckchem), 20 mM etoposide
(Selleckchem), 400 nM gemcitabine (Selleckchem), 10 mM JPM-OEt (syn-
thesized by the Organic Synthesis Facility at Memorial Sloan Kettering
Cancer Center [MSKCC]), 50 mM to 3.2 nM ABT-263 (ApexBio), 10 mM STLC
(Tocris), 2.5 mM ZM447439 (Selleckchem), 500 nM PD0325901 (Selleckchem),
500 nM MK2206 (Selleckchem), and 500 nM gefitinib (Selleckchem) were
added.
Mice
All animal studies were approved by the Institutional Animal Care and Use
Committee of MSKCC under protocol 04-08-022. Wild-type (WT; FVB/n)
and CAG-EGFP (FVB/n) mice were purchased from The Jackson Laboratory
and bred within the MSKCC animal facility. The TS1 orthotopic model of
breast cancer has been reported previously (Shree et al., 2011) and is
described fully, along with in vivo drug treatments, in the Supplemental Exper-
imental Procedures.
Immunoprofiling of Tumors
After counting, single-cell suspensions in FACS buffer (1% IgG Free BSA in
PBS; Jackson ImmunoResearch) were incubated with 1 mL of Fc block (BD)
for every 1 3 106 cells for at least 15 min at 4C. Cells were then stained with
the antibodies for 10 min at 4C, washed with FACS buffer, and resuspended
in FACS buffer containing DAPI (1 mg/mL) for live/dead cell exclusion, unless
otherwise noted. Antibodies used for flow cytometry are listed in Table S1.
For analysis, samples were run on a BD LSR II (Becton Dickinson), and all sub-
sequent compensation and gating were performed with FlowJo analysis soft-
ware (Tree Star).
Intracellular Flow Cytometry and DNA Content Analysis
For intracellular flow cytometry and DNA content analyses, cells were plated
at a density of 1 3 105 per well in a 12-well plate, either alone, with an equal
number of stromal cells, or BMDM CM. For co-cultures only CAG-EGFP
BMDMs were used, and other stromal cell lines were fluorescently labeled
with CellTracker Green CMFDA Dye (Molecular Probes). In experiments
with BMDMs, the media were supplemented with 10 ng/mL recombinant
mouse CSF-1 (R&D Systems). In experiments with MHCII+ BMDMs, the
media were supplemented with 10 ng/mL recombinant mouse CSF-2
(R&D Systems). Twenty-four hours after plating, cells were treated and
then collected at indicated time points by trypsinization. The samples
were then fixed and permeabilized using the Foxp3/Transcription Factor
Staining Buffer Set (eBioscience) and stained overnight at 4C using primary
antibodies at the concentrations listed in Table S2. Allophycocyanin-tagged
secondary antibodies (Jackson ImmunoResearch) were used at a 1:300 dilu-
tion and incubated for 1 hr at room temperature, followed by resuspension
in FACS buffer containing DAPI (5 mg/mL) for DNA content evaluation. For
analysis, samples were run on a BD LSR II (Becton Dickinson), and all sub-
sequent compensation and gating were performed with FlowJo analysis
software (Tree Star).
Live Imaging of Tumor Cell Response to Antimitotic Agents
For live imaging experiments, tumor cells were plated at a density of 1 3 105
per well in a 12-well glass-bottom plate (In Vitro Scientific), either alone, with
an equal number of CAG-EGFP BMDMs, or with BMDM-CM. In experiments
with BMDMs, the media were supplemented with 10 ng/mL recombinant
mouse CSF-1 (R&D Systems). Twenty-four hours after plating, cells were
treated and imaged for 24 hr using a Nikon Eclipse TiE inverted microscope
equipped with an environmental chamber maintained at 35C–37C and
5% CO2. Mitotic arrest duration in live imaging movies was measured using
Nikon Elements Software (Nikon) with at least 30 cells analyzed per treatment
condition per experiment.
Additional information on experimental methods can be found in the Supple-
mental Experimental Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and two tables and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2017.03.038.
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Supplemental Figure 1: CSF-1R Inhibition Depletes Macrophages and Does Not Alter the 
Ability of Taxol to Stabilize Microtubules Within Tumors. Related to Figure 1. 
(A) Mice were treated according to the trial design in Figure 1A and tumors were analyzed at the 
indicated time points (24, 48, 72, 96 hours) relative to Taxol treatment (t=0).  Quantitation by 
image analysis of the percentage of acetylated-αTubulin+ (ac-αTUB+) cells within the tumor 
(left), and representative images of tumor sections (right).  Macrophages are stained with an anti-
CD68 antibody (green). Scale bar = 50 µm. (B) Quantitation by image analysis of the percentage 
of phospho-histone H3+ (pH3) cells within the tumor (left), and representative images of tumor 
sections (right). Scale bar = 50 µm. (C) Flow cytometry analysis of CD11b+ F4/80+ MHCIIlo 
macrophage depletion throughout the course of the trial. Data is represented as the relative 
proportion of viable DAPI- CD45+ leukocytes within the tumor. (D) Flow cytometry analysis of 
CD11b+ F4/80+ MHCIIhi macrophages throughout the course of the trial. Data is represented as 
the relative proportion of viable DAPI- CD45+ cells within the tumor. (E) Flow cytometry 
analysis of CD4+ T cells. (F) Flow cytometry analysis of CD8α+ T cells. n=5 mice in all 
treatment groups at all time points. All data are presented as mean + SEM. Student’s t-test was 
used to assess significance between treatment groups: * p<0.05; ** p<0.01; *** p<0.001. 
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Supplemental Figure 2: Macrophages Mediate Chemoprotective Effects by Suppressing 
Genotoxic Stress. Related to Figure 2.  
(A) Representative histograms of tumor cell DNA content (<2C, 2C, 4C and 8C) in response to 
Taxol treatment alone (50 nM), as measured by flow cytometry. (B) Representative 
immunofluorescence images of DAPI-stained TS1 tumor cells following 24 hours of treatment 
with Taxol. Multinucleated cells are highlighted by white arrows. Scale bar = 20 µm. (C) 
Schematic for the differentiation of BMDMs with CSF-1 and the induction of MHCII expression 
with CSF-2 and IFNg. Histogram on right shows relative levels of MHCII in the different 
differentiation conditions. (D) Flow cytometry analysis of the effect of direct co-culture with 
additional stromal cell lines on the Taxol-induced accumulation of tumor cells (TC) with sub-2C 
DNA content and gH2AX immunoreactivity (n=3 independent experiments). (E) Flow 
cytometric analysis of gH2AX immunoreactivity in TCs following treatment with carboplatin (50 
µM), doxorubicin (300 nM), etoposide (20 µM), or gemcitabine (400 nM), and the effects of co-
culture with BMDMs (n=4 independent experiments). Concentrations were previously 
determined as EC50 values at 48 hours (Shree et al., 2011). (F) Flow cytometric analysis of sub-
2C DNA content tumor cells in response to different chemotherapies and the effects of co-culture 
with BMDMs (n=4 independent experiments). (G) Comparison of the effects of direct co-culture 
and BMDM-conditioned media (BMDM-CM, added to TS1 cells at plating and once at the start 
of the 72-hour experiment) on Taxol-induced accumulation of tumor cells with sub-2C DNA 
content and gH2AX immunoreactivity (n=5 independent experiments). All data are presented as 
mean + SEM. Student’s t-test was used to assess significance between treatment groups: * 
p<0.05; ** p<0.01; *** p<0.001. 
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Supplemental Figure 3: Macrophage-Secreted Factors Suppress Taxol Cytotoxicity 
Without Affecting Microtubule Stabilization. Related to Figure 2.  
(A) Flow cytometric analysis of gH2AX immunoreactivity in tumor cells following treatment 
with Taxol (50 nM) and/ or the pan-cathepsin inhibitor JPM-OEt (10 µM), and the effects of co-
culture with BMDMs (n=3 independent experiments). (B) Flow cytometric analysis of sub-2C 
DNA content TS1 cells following treatment with Taxol (50 nM) and/ or JPM-OEt (10 µM), and 
the effects of co-culture with BMDMs (n=3 independent experiments). (C) Comparison of 
BMDM-CM fractionated with 3kDa molecular weight cut-off spin columns for effects on the 
Taxol-induced accumulation of tumor cells with sub-2C DNA content and gH2AX 
immunoreactivity (n=3 independent experiments). (D) Taxol-induced acetylation of tubulin in 
tumor cells and the lack of effect of BMDM-CM as measured by western blotting. 
Representative western blots are shown. (E) MTT ABT-263 sensitivity assays of TS1 tumor cells 
following Taxol treatment in the presence or absence of BMDM-CM. Tumor cells were treated 
with the indicated concentration of ABT-263 for 6 hours and the relative reduction in cell 
viability was assessed (n=4 independent experiments). (F) The effects of Taxol and BMDM-CM 
(added to TS1 cells at plating and once at the start of the 72-hour assay) on BCL2 family 
members as measured by western blotting.  Representative western blots are shown on the left, 
and quantitation of the data is shown on the right (n=3 independent experiments). All data are 
presented as mean + SEM. Student’s t-test was used to assess significance between treatment 
groups: * p<0.05; ** p<0.01; *** p<0.001. 
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Supplemental Figure 4: Prolonged Mitotic Arrest Drives Genotoxic Stress. Related to 
Figure 3. 
(A) TS1 tumor cells were cultured at 1x105 and 2x105 cells per well in 12-well plates to control 
for effects of increased cell density. Measurement of the duration of tumor cell mitotic arrest in 
response to Taxol (50 nM) by live-imaging microscopy. (B) Measurement of the duration of 
tumor cell mitotic arrest in response to the EG5 inhibitor STLC (10 µM). TS1 cells were cultured 
alone or in combination with BMDMs. (C) Flow cytometric analysis of gH2AX 
immunoreactivity in tumor cells in response to treatment with Taxol (50 nM) and ZM447439 (5 
µM) for 24 hours (n=3 independent experiments). (D) As in (C), except that tumor cell phospho-
p53(ser15) immunoreactivity is analyzed by flow cytometry (n=3 independent experiments). (E) 
Flow cytometric analysis of phospho-histone H3+ mitotic tumor cells following 8 hours of Taxol 
treatment across a range of drug concentrations (n=4 independent experiments). (F) 
Representative histograms of tumor cell DNA content following 24 hours of Taxol treatment 
across a range of drug concentrations. (G) Comparison of the effects of co-culture with BMDMs 
on the accumulation of tumor cells with sub-2C DNA content at 6.25 and 12.5 nM 
concentrations of Taxol (n=4 independent experiments). (H) Clonogenic assay measuring the 
effects of BMDM-CM on inhibition of tumor cell colony formation by 6.25 and 12.5 nM 
concentrations of Taxol. Representative images are shown on the left and quantification of 
crystal violet staining is shown on the right (n=4 independent experiments). Scale bar = 5 mm. 
Data from live imaging experiments are presented as mean + interquartile range for a single 
representative example of three independent experiments. Data from all other experiments are 
presented as mean + SEM.  Student’s t-test was used to assess significance between treatment 
groups: ns, non-significant; * p<0.05; *** p<0.001. 
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Supplemental Figure 5: The Effect of Survival Pathway Inhibitors on Cancer Cell Viability 
Following Taxol-Induced Mitotic Slippage. Related to Figure 4. 
(A) Flow cytometric analysis of sub-2C DNA content in TS1 tumor cells in response to Taxol 
(50 nM) and/ or the AKT inhibitor MK2206 (500nM). TS1 cells were treated alone or in co-
culture with BMDMs (n=3 independent experiments). (B) Validation of AKT inhibition in TS1 
cells by western blotting following 24 hours of treatment with MK2206 (500 nM) (C) Flow 
cytometric analysis of sub-2C DNA content tumor cells in response to Taxol (50 nM) and the 
EGFR inhibitor gefitinib (500 nM). Tumor cells were treated alone or in co-culture with 
BMDMs (n=3 independent experiments). (D) Flow cytometric analysis of sub-2C DNA content 
tumor cells in response to Taxol (50 nM), PD0325901 (500 nM), and BMDM-CM (n=3 
independent experiments). (E) A single representative experiment is plotted measuring the 
duration of mitotic arrest in TS1 cells treated with Taxol (50 nM) and PD0325901 (500 nM) in 
the presence or absence of BMDM-CM. In each experiment, 40 cells were scored per condition 
and this was repeated in three independent experiments. (F) DNA content analysis of tumor cell 
colonies shown in Figure 4D. Quantification of treatment groups are shown above with 
representative histograms below (n=4 independent experiments). (G) Analysis of ERK1/2 and 
NFkBp65 signaling in TS1 cells following 48 hours of treatment with Taxol (50 nM) in the 
presence or absence of BMDM-CM supplemented daily (denoted BMDM-CM(+)) and the MEK 
inhibitor PD0325901 (500 nM). Representative western blots are shown. A.U.C. quantification 
of band intensities is displayed on the right as a ratio of phosphorylated/ total NF-kBp65 (n=3 
independent experiments). Data for mitotic arrest duration are presented as mean ± interquartile 
range. All other data are presented as mean ± SEM. Student’s t-test was used to assess 
significance between treatment groups: ns, non-significant; * p<0.05; ** p<0.01; *** p<0.001. 
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Supplemental Figure 6: Preclinical Evaluation of Combined Macrophage Targeting and 
Taxol Treatment. Related to Figure 4. 
(A) Model summarizing the findings in this study. TAM-secreted factors reduce the duration of 
mitotic arrest in tumor cells induced by antimitotic drugs. Following mitotic slippage, tumor 
cells co-cultured with macrophages or treated with macrophage-CM have reduced levels of 
γH2AX and p53 phosphorylation resulting in lower levels of interphase cell death and greater 
clonogenic viability. The ability of TAMs to modulate the cancer cell response to Taxol is 
sensitive to MEK inhibition. (B) Preclinical trial design for combined acute CSF-1R and 
MEK1/2 inhibition with single dose Taxol treatment in an orthotopic mouse model of breast 
cancer. BLZ945 treatment is initiated 3 days prior to Taxol treatment to pre-deplete TAMs and 
continued for 3 additional days following the single Taxol dose. PD0325901 is administered for 
3 days concurrent with the single Taxol dose. Data in (C, D) are from whole tumors isolated 72 
hours post-Taxol treatment according to the trial design in (B). Quantification by image analysis 
of the percentage of (C) gH2AX+, and (D) cleaved caspase 3+ (CC3+) cells within the tumor 
(left), and representative images of tumor sections (right). Scale bar = 50 µm. n=10 mice in all 
treatment groups. (E) Preclinical trial design for combined CSF-1R or MEK1/2 inhibition with 
weekly Taxol treatment in an orthotopic mouse model of breast cancer. BLZ945 treatment is 
initiated 3 days prior to Taxol treatment to pre-deplete TAMs and continued daily until endpoint. 
PD0325901 is administered for 3 days concurrent with each Taxol dose. All data are presented as 
mean ± SEM. Student’s t-test was used to assess significance between treatment groups: * 
p<0.05; ** p<0.01; *** p<0.001. 
	
Supplemental Table 1: List of antibodies used for flow cytometry analysis. Related to 
Figures 1 and S1. 
 
Antigen Species Clone Vendor Fluorophore Dilution 
CD45 Rat 30-F11 BioLegend A700 1:500 
CD11b Rat M1/70 BioLegend PE 1:200 
F4/80 Rat BM8 BioLegend PE-Cy7 1:250 
I-A/I-E (MHCII) Rat M5/114.15.2 BioLegend APC 1:500 
Ly6C Rat HK1.4 BioLegend APC-Cy7 1:500 
Ly6G Rat 1A8 BioLegend FITC 1:500 
CD4 Rat RM4-5 BioLegend PE 1:500 
CD8a Rat 53-6.7 BioLegend APC 1:200 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 2: List of primary antibodies. Related to Figures 1, 2, 4, S1, S2, S3, S4, 
S5 and S6. 
 
Antigen Species Clone Vendor Dilution 
BCL-2 Rabbit 50E3 Cell Signaling WB 1:1000 
BCL-XL Rabbit 54H6 Cell Signaling WB 1:1000 
cleaved Caspase-3 (Asp175) Rabbit 5A1E Cell Signaling IF 1:500 WB 1:1000 
cleaved Caspase-8 (Asp387) Rabbit D5B2 Cell Signaling WB 1:1000 
cleaved Caspase-9 (Asp353) Rabbit - Cell Signaling WB 1:1000 
CD68 Rat FA-11 Serotec IF 1:1000 
Phosphor-AKT (Ser473) Rabbit D9E Cell Signaling WB 1:1000 
AKT Rabbit 11E7 Cell Signaling WB 1:1000 
phospho-ERK1/2 (Thr202/Tyr204) Rabbit D13.14.4E Cell Signaling WB 1:1000 
ERK1/2 Mouse 3A7 Cell Signaling WB 1:1000 
GAPDH Rabbit 14C10 Cell Signaling WB 1:5000 
phospho-Histone H2A.X (Ser139) Rabbit 20E3 Cell Signaling IF 1:500 FC 1:400 
phospho-Histone H3 (Ser10) Rabbit D2C8 Cell Signaling IF 1:1600 FC 1:1600 
Ki67 Rabbit SP6 Vector IF 1:100 
MCL1 Rabbit Y37 Abcam WB 1:1000 
Phosphor-NFkB p65 (Ser536) Rabbit 93H1 Cell Signaling WB 1:1000 
NFkB p65 Rabbit D14E12 Cell Signaling WB 1:1000 
phospho-p53 (Ser15) 
 Rabbit D4S1H Cell Signaling FC 1:1000 
acetyl-α-Tubulin (Lys40) Rabbit D20G3 Cell Signaling IF 1:800 WB 1:1000 
α/β-Tubulin 
 Rabbit - Cell Signaling WB 1:1000 
Abbreviations: FC: flow cytometry; IF: immunofluorescence; WB: western blot. 
 
 
 
 
 
Supplemental Experimental Procedures 
 
Mice 
All animal studies were approved by the Institutional Animal Care and Use Committee of 
MSKCC under protocol 04-08-022. Wild-type (WT, FVB/n) and CAG-EGFP (FVB/n) mice 
were purchased from The Jackson Laboratory and bred within the MSKCC animal facility. For 
syngeneic orthotopic implantations, 5 × 105 TS1 tumor cells were implanted 1:1 in Matrigel 
(BD, growth factor-reduced) into the fourth mammary fat pads (MFP) of wild-type FVB/n mice 
aged 6–9 wk. Tumors were allowed to grow to ~200mm3 (which was approximately 3 weeks 
following implantation) before any treatment was initiated. External tumor measurements were 
made using precision calipers, and tumor volumes (TV) were calculated according to the 
following formula: TV = (a)(b2) × π/6 (a = longest dimension, and b = largest dimensional 
orthogonal to a). Individual tumor volumes were normalized to the time of initial Taxol 
treatment to evaluate response in a manner that weights each individual tumor equally. For tissue 
harvesting and analysis, mice were anesthetized with Avertin and perfused with saline. For tissue 
sectioning and staining, tumor tissues were post-fixed in 10% formalin for one hour before 
incubation in a 30% sucrose solution overnight and OCT (Tissue-Tek) embedding for frozen 
tissue sectioning. For analysis by flow cytometry, single cell suspensions were generated by 
using the Mouse Tumor Dissociation Kit (Miltenyi) in combination with the gentleMACS Octo 
Dissociator (Miltenyi). 
 
In vivo drug treatment 
The CSF-1R inhibitor BLZ945 (supplied by Novartis) was synthesized as described previously 
(Pyonteck et al., 2013). For administration to mice, BLZ945 was formulated in 20% Captisol at a 
concentration of 12.5 mg/ml. For in vivo dosing, mice received 200 mg BLZ945 per kg body 
weight or vehicle (20% Captisol) by oral gavage once daily. The microtubule-stabilizing agent 
Taxol (Sigma) was used at the previously determined maximum tolerated dose (Sharma and 
Straubinger, 1994). Accordingly, Taxol was dissolved in a 1:1:2 cremophor EL:ethanol:PBS 
solution (Taxol stock maintained in 1:1 cremophor EL:ethanol, then mixed fresh 1:1 with PBS 
prior to injection) and administered by intraperitoneal injection at a dose of  50 mg/kg. The MEK 
inhibitor PD0325901 (Selleckchem) was used at a concentration of 10mg/kg, a dose with 
demonstrated efficacy in mouse models of cancer (Jessen et al., 2013). The inhibitor was 
reconstituted in 0.5% methylcellulose solution with 0.2% Tween 80 and administered daily by 
oral gavage. 
 
Staining and analysis of tissue sections 
For frozen tissues, 10 µm sections were permeablized in 0.5% Trition X-100, preincubated with 
1× PNB-blocking buffer (Perkin Elmer Life Sciences), and incubated with the primary antibody 
of interest overnight at 4°C. Appropriate Alexa dye-tagged secondary antibodies (Invitrogen) 
were used at a 1:500 dilution and incubated for 1 h at room temperature, followed by incubation 
in 2 µg/mL DAPI solution (Invitrogen) for 5 min. Species-matched immunoglobulins were used 
as negative controls. Slides were mounted in Fluorescent Mounting Media (Dako), and the tissue 
sections were visualized under a Carl Zeiss (Oberkochen, Germany) Axioimager Z1 microscope 
equipped with an ApoTome.2. Staining analyses were performed by using a TissueGnostics 
(Vienna, Austria) slide scanning platform and TissueQuest analysis software. This automated 
analysis platform was used to quantify the number of positive cell counts in an unbiased manner 
as previously described (Pyonteck et al., 2013; Quail et al., 2016). 
 
Isolation and differentiation of bone marrow-derived macrophages (BMDMs) 
For bone marrow (BM) isolation followed by macrophage derivation, femurs and tibiae were 
harvested from WT or CAG-EGFP FVB/n female mice between 8-10 weeks of age. Under 
sterile conditions the marrow was flushed from the bones, passed through a 40-µm strainer, and 
cultured in 30 ml Teflon bags (PermaLife PL-30) in DMEM and 10% FBS supplemented with 
10 ng ml−1 recombinant mouse CSF1 (R&D Systems). BM cells were cultured in Teflon bags for 
7 d with fresh CSF1–containing medium changes every other day to induce macrophage 
differentiation, after which they were referred to as BMDMs. For the generation of MHCII+ 
BMDMs, bone marrow isolates were treated with 10 ng ml−1 recombinant mouse CSF-1 for 5 
days followed by treatment with 10 ng ml−1 recombinant mouse CSF-2 (R&D Systems) and 50 
ng ml−1 recombinant mouse IFNg (R&D Systems) for 48 hours (see schematic in Figure S2C). 
Experiments using MHCII+ BMDMs were supplemented with 10 ng ml−1 recombinant mouse 
CSF-2. For all experiments where BMDMs were used in co-cultures, bone marrow isolated from 
CAG-EGFP mice was used. 
 
BMDM conditioned media (CM) experiments 
Experiments with CM were conducted as for the co-culture experiments, with CM used in place 
of macrophages throughout the course of the experiment, including cell plating prior to 
treatment. Medium that had been conditioned for 24 hours by wild-type BMDMs, and passed 
through 0.45-µm filters to remove cellular debris, was then added 1:1 with fresh medium to 
tumor cell monocultures. Controls received fresh medium containing 10% serum. For 
experiments where CM was supplemented daily (denoted BMDM-CM(+)), at hour 24 and 48, 
either CM or regular media was added to the culture in volumes equal to 50% of the volume at 
hour 0. Taxol and/ or PD0325901 was also added to maintain the specified concentration of 
drug. For fractionation experiments, serum-free media was conditioned for 24 hours, then passed 
through a 0.45-µm filter prior to fractionation with Amicon Ultra-15 Centrifugal Filter Unit with 
Ultracell-3 kDa membrane (EMD Millipore). Volumes were then normalized by addition of 
serum-free media, and then fetal bovine serum was added to all samples at a final concentration 
of 10%. 
 
Protein isolation, labeling, and western blotting 
Samples were lysed in NP-40 lysis buffer (0.5% NP-40, 50 mM Tris-HCl [pH 7.5], 50 mM 
NaCl, 1x complete Mini protease inhibitor cocktail (Roche), 1x PhosSTOP phosphatase inhibitor 
cocktail (Roche)), and protein quantified by BCA assay (Pierce). Protein lysates were loaded (20 
µg per lane) onto SDS-PAGE gels and transferred to PVDF membranes for immunoblotting. 
Membranes were blocked with TBS-T containing 5% non-fat milk and then probed overnight at 
4°C using primary antibodies at the concentrations listed in Supplemental Table 2. 
Immunoreactivity was then detected using HRP-conjugated anti-mouse or anti-rabbit (Jackson 
ImmunoResearch) antibodies using chemiluminescence detection (Peirce). Bands from Western 
blots were quantified in the dynamic range using the Gel Analysis module in ImageJ software. 
For all experiments analyzing the effects of BMDM-CM on signal transduction, BMDM-CM 
was supplemented daily (denoted BMDM-CM(+)).  
 
ABT-263 sensitization assay 
For ABT-263 sensitization assays, cells were plated at 5x103 in 96-well plates and after 24 hours 
treated with Taxol (50 nM). At indicated time points media was removed and replaced with 
media containing a dilution series of the BH3 mimetic ABT-263 ranging from 50 µM to 3.2 nM. 
Cells were incubated in ABT-263 containing media for 6 hours at 37° C before being replaced 
with fresh media and the metabolic viability of cells was measured by MTT assay (Roche). Data 
was then normalized to the controls not treated with ABT-263. 
 
Clonogenic drug resistance assays 
Cells were filtered through a 40 µm mesh strainer (Falcon) to remove cell doublets and larger 
cell aggregates and plated with or without BMDM CM at a density of 5x103 cells per well in 6-
well plates. After 24 hours of attachment, wells were treated with 50 nM Taxol. After 24 hours 
of treatment Taxol was removed and replaced with fresh media with or without BMDM CM. 
This was repeated every 48 hours for a total assay length of 8 days at which point cells were 
stained with 0.3% crystal violet (Sigma). For experiments where the MEK inhibitor PD90325901 
was included the drug treatment lasted for 72 hours, beginning at the same time as Taxol 
treatment. Representative images of the wells were taken and then the crystal violet staining was 
quantified by solubilization with 1% SDS and absorbance measurements made at 570 nm using a 
SpectraMax plate reader (Molecular Devices). For DNA content analyses, colonies were 
harvested with trypsin, then fixed and permeabilized using the Foxp3/Transcription Factor 
Staining Buffer Set (Ebioscience) and stained with DAPI (5µg/ml). For analysis, samples were 
run on a BD LSR II (Becton Dickinson), and analyzed with FlowJo analysis software (TreeStar). 
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